Study on the clinical characteristics and genotype of direct-acting antiviral therapy failure in treatment of hepatitis C

Abstract

Abstract: Objective To explore the clinical and genotypic characteristics of patients with chronic hepatitis C (CHC) who experienced treatment failure with direct-acting antiviral drugs (DAAs). Methods Between September 2021 and December 2022, 28 patients who failed in DAA treatment in our hospital were selected as the observation group, and 100 patients who succeeded in DAA treatment in the same period were selected as the control group. Liver function was detected by enzyme method, hepatitis C virus (HCV) genotype was detected by PCR- reverse hybridization method, and drug resistance-associated substitution mutation (RAS) fragment was detected by Sanger sequencing method. The clinical characteristics and genotype characteristics of patients in DAA observation group were analyzed. Results There were 23 cases (82.1%) and 34 cases (34.0%) with HCV-RNA load > 10⁵ IU/ml in the observation group and the control group respectively, and the difference was statistically significant (χ²=20.526, P=0.001). In DAA treatment observation group, the TBIL and DBIL of male patients were 14.61(10.98-20.78) μmol/L and 4.94(3.08-7.48) μmol/L, respectively, which were significantly higher than those of female patients [6.65(4.90-8.40) μmol/L and 2.50(1.78-3.07) μmol/L, Z=- 2.018, -2.456, P=0.010 and 0.010, respectively]. Three HCV genotypes were detected in the included patients, namely 1b, 2a and 3b, and 26 of them were undetected. HCV 1b, 2a and 3b genotypes in the observation group were 11 (39.3%), 6 (21.4%) and 5 (17.8%), of while in the control group were 56 (56.0%), 15 (15.0%) and 9 (9.0%), respectively. NS5A and NS5B2 gene fragments were detected in DAA treatment observation group, but the incidence of RAS was different. Conclusion Patients who experience DAA treatment failure are influenced by factors such as patient gender, viral load, genotypic variations, and types of RAS.

Key words: Direct-acting antiviral drugs, Chronic hepatitis C, Genotype, Resistance-associated substitutions (RAS)

CUI Rui, MA Zhi, YANG Tian-fen, ZHOU Hao-jun, LI Ping-ping. Study on the clinical characteristics and genotype of direct-acting antiviral therapy failure in treatment of hepatitis C[J]. Chinese Hepatolgy, 2024, 29(8): 943-946.

References 20

[1]	Westerhoff M, Ahn J. Chronic hepatitis C and direct acting antivirals[J]. Surg Pathol Clin,2018,11(2):287-296.
[2]	Afzal M, Ali A, Sheikh N, et al. Peripheral expression of CXCL10 gene in chronic hepatitis C patients treated with sofosbuvir, daclatasvir, and ribavirin[J]. J Interferon Cytokine Res,2020,40(6):301-309.
[3]	Devan P, Tiong KLA, Neo JE, et al. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral-experienced hepatitis C virus patients: a systematic review and meta-analysis[J]. Viruses,2023 ,15(7):1489.
[4]	杨宇晴, 尚佳, 卢诚震, 等. 直接抗病毒药物治疗丙型肝炎失败的影响因素分析[J]. 临床肝胆病杂志, 2022, 38(5):1059-1063.
[5]	Bellocchi MC, Aragri M, Carioti L, et al. NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients[J]. Cells, 2019,8(7):666.
[6]	中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版) [J]. 中华传染病杂志, 2020, 38(1):9-28.
[7]	Roudot TF. Epidemiology of hepatitis C virus infection[J]. Clin Res Hepatol Gastroenterol, 2021,45(3):101596.
[8]	Danishwar M, Jamil Z, Khan S, et al. Persistence of cryoglobulinemic vasculitis after DAA induced HCV cure[J]. J Clin Med, 2022,11(4):984.
[9]	Aregay A, Owusu SS, Deterding K, et al. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell response[J]s. J Hepatol, 2019,71(5):889-899.
[10]	Pawlotsky JM. Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures[J]. Semin Liver Dis, 2019,39(3):354-368.
[11]	Sarrazin C. Treatment failure with DAA therapy: Importance of resistance[J]. J Hepatol, 2021,74(6):1472-1482.
[12]	陈宏宇, 徐小元. 直接抗病毒药物在基因2、3型HCV中的耐药相关研究[J]. 临床肝胆病杂志, 2020, 36(11):2553-2556.
[13]	Fedorchenko SV, Martynovych T, Klimenko Z, et al. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors[J]. J Med Virol, 2021, 93(8):4975-4981.
[14]	贺秋凤, 胡蓉, 曾义岚, 等. 索磷布韦/维帕他韦联合或不联合利巴韦林治疗基因3型慢性丙型肝炎病毒感染者的疗效及安全性:一项真实世界研究[J]. 中国肝脏病杂志,2022, 14(1):6-13.
[15]	Murgod SE, Ahmed S, Almutairi N, et al. Safety and efficacy of elbasvir/grazoprevir in patients infected with hepatitis C virus genotype 4 in Qassim region of Saudi Arabia[J]. Int J Health Sci (Qassim), 2023,17(2):22-27.
[16]	王梅, 杨兴林, 张流, 等. 贵州地区HCV感染者基因型分布特征[J]. 临床肝胆病杂志, 2020, 36(2):309-313.
[17]	Catalli L, Martens SK, Terrault NA, et al. Novel NS5B resistance-associated substitution emerges under failing sofosbuvir/ledipasvir therapy[J]. Clin Liver Dis (Hoboken), 2019,13(3):74-78.
[18]	阳光, 苏明华, 江建宁, 等. 广西地区HCV1b型感染者NS5B区基因耐药多态性分析[J]. 临床肝胆病杂志, 2019, 35(5):992-995.
[19]	Rossetti B, Paglicci L, Di Maio VC, et al. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019[J]. Infez Med, 2021,29(2):242-251.
[20]	García-Crespo C, Gallego I, Soria ME, et al. Population disequilibrium as promoter of adaptive explorations in hepatitis C virus[J]. Viruses, 2021,13(4):616.